Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

NCT02134717 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Poor recruitment

Conditions

Sarcoidosis

Interventions

DRUG: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks
PROCEDURE: Bronchoscopy with bronchoalveolar lavage
PROCEDURE: venipunctures
PROCEDURE: Skin biopsy

Sponsor

Kevin F. Gibson

Collaborators

[object Object]